Holen Sie sich die Stockscreener-App
5.06
8.83%
-0.49
Handel nachbörslich:
5.10
0.04
+0.79%
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
October 13, 2026 Deadline: Join Class Action Lawsuit Against Aardvark Therapeutics, Inc. (AARD)Contact Levi & Korsinsky - accessnewswire.com
Investors Urged to Contact Levi & Korsinsky for Information Before October 13, 2026Aardvark Therapeutics, Inc. (AARD) - ACCESS Newswire
Aardvark Therapeutics, Inc. (AARD) Gets a Hold from RBC Capital - The Globe and Mail
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit ... - Black Hills Pioneer
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and DirectorsAARD - PR Newswire
AARD Lead Plaintiff Deadline is Quickly Approaching - GlobeNewswire
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Aardvark Therapeutics' ARD-101 Path Forward May Be Challenging, RBC Says - marketscreener.com
Class Action Alert: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. (AARD) Investors of October 13, 2026 Deadline - accessnewswire.com
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. LawsuitAARD - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AARD LAWSUIT ALERT: Levi & Korsinsky Notifies Aardvark Therapeutics, Inc. InvestorsLead Plaintiff Deadline October 13, 2026 - ACCESS Newswire
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline - PR Newswire
Lawsuit alleges Aardvark Therapeutics misled in... - Pluang
Kuehn Law Encourages Investors of Aardvark Therapeutics, Inc. to Contact Law Firm - Morningstar
Did You Lose Money on Aardvark Therapeutics, Inc. (AARD)? Levi & Korsinsky Urges Investors to Act Before October 13, 2026 - ACCESS Newswire
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026AARD - PR Newswire
Layoff Tracker: Novo workforce down 13,000 - BioSpace
מועד אחרון לתביעה ייצוגית נגד AARDVARK: רוזן, יועץ למשקיעים מיומן, קורא למשקיעי Aardvark Therapeutics, Inc. לשכור ייצוג משפטי לקראת מועד חשוב בתביעה ייצוגית בניירות הערך – AARD - GlobeNewswire Inc.
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - TMX Newsfile
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Aardvark - globenewswire.com
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT - GlobeNewswire
Important Notice to Long-Term Shareholders of Aardvark - GlobeNewswire
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
AARD Deadline: AARD Investors with Losses in Excess of $100K Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - AOL.ca
Deadline Alert: Aardvark Therapeutics, Inc. (AARD) - GlobeNewswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - mykxlg.com
Lost Money on Aardvark Therapeutics, Inc. (AARD)? Urged to Join Class Action Before October 13, 2026Contact Levi & Korsinsky - ACCESS Newswire
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AARD IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, - GlobeNewswire
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lowey Dannenberg, P.C. is Investigating Aardvark - GlobeNewswire
AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action NoticeContact Levi & Korsinsky - The Chronicle-Journal
Aardvark Therapeutics Insider Sold Shares Worth $394,957, According to a Recent SEC Filing - Moomoo
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101 - TMX Newsfile
Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action - TMX Newsfile
AARD Deadline Alert: SueWallSt Reminds Aardvark Therapeutics, Inc. (AARD) Investors of Securities Class Action Deadline on October 13, 2026 - PR Newswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AARD Investor Notice: Hagens Berman Alerts Investors in - GlobeNewswire
AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD - FinancialContent
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AARDVARK THERAPEUTICS, INC. INVESTORS WITH LOSSES HAVE - GlobeNewswire
RBC Capital Maintains Aardvark Therapeutics(AARD.US) With Hold Rating, Maintains Target Price $6 - Moomoo
AARD DEADLINE: Levi & Korsinsky Reminds Aardvark - GlobeNewswire
Sun Nelson Disposes 76,754 Shares of Aardvark Therapeutics (NASDAQ: AARD) at $5.00-$5.18 - Kalkine Media
Class Action Lawsuit Filed Against Aardvark Therapeutics, Inc. (AARD)Recover LossesContact Levi & Korsinsky Before October 13, 2026 - ACCESS Newswire
Aardvark Therapeutics, Inc. (AARD) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 13, 2026 - ACCESS Newswire
Levi & Korsinsky Urges Aardvark Therapeutics, Inc. (AARD) Shareholders to Act Before Lead Plaintiff Deadline October 13, 2026 - ACCESS Newswire
Class Action Lawsuit Filed: Aardvark Therapeutics, Inc. (AARD) – Join by October 13, 2026 – Contact Levi & Korsinsky - ACCESS Newswire
AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits
Aardvark Therapeutics COO Nelson Sun sells $394,957 in shares By Investing.com - Investing.com Canada
Aardvark Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sun Nelson - Moomoo
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):